This finding indicates that PD-L1 still has a great defect as a biomarker for predicting the efficacy of immunotherapy, and indirectly supports the idea that PD-L1 expression is highly heterogeneous in tumor tissues. The gene discussed is CD274; the disease is neoplasm.